ResultsIQ

ResultsIQ › Latest results › Rossari Biotech Limited

Rossari Biotech Limited Q1 FY26 results deck summary

NSE: ROSSARI · BSE: 543213

Results deck of 19 Jul 2025, summarised by AI from the filing.

Q1 FY26 revenue from operations ₹543.7 cr, up 11.0% YoY, with HPPC growing 16% and EBITDA margin at 12.5%.

Key takeaways

  1. Revenue Q1 FY26 revenue from operations was ₹543.7 cr (Q1 FY25: ₹489.7 cr, +11.0%).
  2. Guidance Management expects Institutional and B2C businesses to demonstrate healthy growth on an annual basis.
  3. Change EBITDA margin declined to 12.5% in Q1 FY26 from 13.3% in Q1 FY25.
  4. Driver HPPC segment grew 16% YoY, supported by deeper market penetration and traction across agrochemicals, personal care, institutional and consumer business.
  5. Risk Institutional and B2C businesses remained soft during the quarter.

Original filing on BSE

Rossari Biotech Limited Q1 FY27 results

As filed: Revenue ₹697 cr (+28% year on year), EBITDA ₹80.6 cr (+17% year on year), PAT ₹35.1 cr (+3% year on year), EBITDA margin 11.6% (−112 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹685 cr (+18% year on year), EBITDA ₹77.3 cr (+10% year on year), PAT ₹46.0 cr (+35% year on year), EBITDA margin 11.3% (−79 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin fell 79 bps year on year. Other income 30% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +6.5% in 30 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹582 cr (+13% year on year), EBITDA ₹68.9 cr (+8% year on year), PAT ₹32.8 cr (+2% year on year), EBITDA margin 11.8% (−64 bps). Score 52 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 64 bps year on year. Revenue rose ₹68.7 cr on a year ago, more than the ₹49.0 cr it added the year before. Share price after the results: +0.7% in 30 days (Nifty 500: −0.1%).
  • H1 FY26: Revenue ₹1,130 cr, EBITDA ₹140 cr, PAT ₹70.0 cr, EBITDA margin 12.4%. Not scored. No consolidated results for the same half-year last year to compare yet (consolidated revenue ₹1,130 cr). Scored once a year-earlier consolidated half-year exists. Share price after the results: −4.6% in 30 days (Nifty 500: +2.0%).
  • Q1 FY26: Revenue ₹544 cr (+11% year on year), EBITDA ₹69.0 cr (+6% year on year), PAT ₹34.0 cr (−3% year on year), EBITDA margin 12.7% (−58 bps). Score 36 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin fell 58 bps year on year. Revenue fell 6% from last quarter. Share price after the results: −14.0% in 30 days (Nifty 500: −1.5%).
  • Q4 FY25: Revenue ₹580 cr (+23% year on year), EBITDA ₹70.0 cr (+9% year on year), PAT ₹34.0 cr (0% year on year), EBITDA margin 12.1% (−146 bps). Score 50 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin fell 146 bps year on year. Share price after the results: −5.9% in 28 days (Nifty 500: +4.3%).
  • Q3 FY25: Revenue ₹513 cr (+11% year on year), EBITDA ₹64.0 cr (+2% year on year), PAT ₹32.0 cr (−6% year on year), EBITDA margin 12.5% (−110 bps). Score 24 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 110 bps year on year. Profit fell 9% from last quarter.
  • Q2 FY25: Revenue ₹498 cr (+3% year on year), EBITDA ₹66.0 cr (+3% year on year), PAT ₹35.0 cr (+6% year on year), EBITDA margin 13.3% (0 bps). Score 38 of 100, Below trend. EBITDA margin was flat year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Rossari Biotech Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.